Drug Trial Radar · NCT01905943
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
Last checked: Nov 19, 2026Latest source record: Oct 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
979
Actual
Start
Nov 4, 2013
Primary completion
Dec 29, 2016
Study completion Oct 8, 2018
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Post-Authorization Safety Study. Participants will receive 6 cycles of single-agent obinutuzumab or obinutuzumab in combination with chemotherapy at the investigator's discretion. Each participant will be followed until 30 months after the last participant has been enrolled. Total length of the study is anticipated to be approximately 5 years.
Conditions
- Chronic Lymphocytic Leukemia
Interventions
BendamustineDrug
Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
ChlorambucilDrug
Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
CyclophosphamideDrug
Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
FludarabineDrug
Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
ObinutuzumabDrug
Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Baseline up to time of primary completion (3 years)
- Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: Baseline up to time of primary completion (3 years)
- Number of Participants With Adverse Events of Particular Interest (AEPIs)Time frame: Baseline up to time of primary completion (3 years)
Locations
174 sites in 31 countries. Site status is shown where the registry gives one.
Hospital Iturraspe
Santa Fe, Argentina
Hospital Erasme; Neurologie
Brussels, Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium
CHU Sart-Tilman
Liège, Belgium
Sint Augustinus Wilrijk
Wilrijk, Belgium
University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept
Banja Luka, Bosnia and Herzegovina
University Clinical Center Sarajevo, Clinic for Hematology
Sarajevo, Bosnia and Herzegovina
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Hospital Amaral Carvalho
Jaú, São Paulo, Brazil
Instituto de Ensino e Pesquisa Sao Lucas - IEP
São Paulo, São Paulo, Brazil
Hospital Sirio Libanes; Centro de Oncologia
São Paulo, São Paulo, Brazil
Hospital Estadual do Servidor Publico; Hematologia
São Paulo, São Paulo, Brazil
Hospital das Clinicas - FMUSP; Hematologia
São Paulo, São Paulo, Brazil
Hospital Santa Marcelina;Oncologia
São Paulo, São Paulo, Brazil
CHU de Quebec - Hopital de l'Enfant-Jesus; Unite de Recherche en Hematologie et Oncologie
Québec, Canada
Cancer Care Manitoba
Winnipeg, Manitoba, Canada
Regional health authority A vitalite health network
Moncton, New Brunswick, Canada
Queen Elizabeth II Health Sciences Centre; Oncology
Halifax, Nova Scotia, Canada
Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials
Barrie, Ontario, Canada
Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie
Greenfield Park, Quebec, Canada
Hopital Maisonneuve- Rosemont; Oncology
Montreal, Quebec, Canada
Centre de sante et de services sociaux Rimouski Neigette
Rimouski, Quebec, Canada
Saskatoon Cancer Centre; Uni of Saskatoon Campus
Saskatoon, Saskatchewan, Canada
Cairo University Hospital Al Kasr El Ainy
Cairo, Egypt
National Cancer Institute
Cairo, Egypt
North Estonia Regional Hospital; Hematology
Tallinn, Estonia
Tartu Uni Hospital; Hematology - Oncology Clinic
Tartu, Estonia
Kuopio University Hospital
Kuopio, Finland
Tampere University Hospital; Hematology
Tampere, Finland
Turku Uni Central Hospital; Dept of Internal Medicine
Turku, Finland
Hotel Dieu; Medecine D
Angers, France
Ch Victor Dupouy; Hematologie
Argenteuil, France
Hopital Augustin Morvan; Hematologie
Brest, France
Hopital Cote De Nacre; Hematologie Biologique
Caen, France
Chu Estaing; Hematologie Clinique Adultes
Clermont-Ferrand, France
Hopital Henri Mondor; Hematologie Clinique
Créteil, France
Chu Site Du Bocage;Hematologie Clinique
Dijon, France
Centre Hospitalier Departemental Les Oudairies
La Roche-sur-Yon, France
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.